+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 65Years
All Genders
ID06525636

Multicenter, Open-label Study of Subcutaneous KK8123 in Adults with X-linked Hypophosphatemia Evaluating Safety and Dose Escalation

Led by Kyowa Kirin Co., Ltd. · Updated on 2026-09-21

39

Participants Needed

10

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying KK8123 in adults with X-linked hypophosphatemia XLH to evaluate its safety, tolerability, pharmacokinetics PK, and pharmacodynamics PD. This Phase 12, multicenter, open-label study includes a screening period, dose escalation, and an optional safety extension. The goal is to understand how KK8123 behaves in the body and its effects on XLH symptoms. Participants will receive subcutaneous doses of KK8123 in escalating amounts during Part 1, which includes a treatment period followed by observation. Part 2 offers an optional extension to continue safety monitoring. Doses range from low to mid-high levels, and the study assesses various biological markers and labs over a period of up to 48 weeks. During the trial, participants undergo regular assessments including blood tests for phosphorus levels, hematology, clinical chemistry, hormone levels, vital signs, echocardiograms, and renal ultrasounds. Researchers monitor for treatment-emergent adverse events and measure drug concentration levels. The study lasts up to 48 weeks with continuous safety and efficacy monitoring throughout the treatment and extension phases.

CONDITIONS

Brief Title

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

Research Team

K

Kyowa Kirin

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here